Compare Amylx Pharmaceuticals Inc (AMLX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.36 (market cap $2.60B), while Marsh & McLennan Companies, Inc. trades at $189.1 (market cap $90.13B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 34.7× Amylx Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.1% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MRSH | |
|---|---|---|
Market Cap | $2.60B | $90.13B |
Sector | Health | Financials |
52-Week High | $24.19 | $211.21 |
52-Week Low | $7.82 | $157.32 |
Enterprise Value | $2.36B | $110.81B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Marsh & McLennan (MRSH) trades at $188.81, down 1.04% today, but maintains a bullish technical trend with strong fundamentals. The company reported Q2 2026 EPS of $2.96, beating estimates, and has consistently exceeded earnings expectations. Revenue growth remains solid at 6% in Q2 2026, driven by risk and consulting services. Recent acquisitions, like the planned purchase of Accel Holdings, aim to expand its Midwest insurance reach.
The outlook is positive with a consensus price target of $202.89, suggesting 7.5% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Analyst sentiment is mixed with 30.3% buy ratings but 66.7% hold, indicating cautious optimism. Institutional activity shows new positions by Ashton Thomas Securities and Bank of Nova Scotia, supporting long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
